Rapid Gonorrhea Testing

Working to reduce the spread of gonorrhea through the development of a rapid and accurate point-of-care test

A Growing Public Health Need

 

With the number of cases on the rise and the emergence of antibiotic resistant strains on the horizon1, diagnosing and treating gonorrhea is an increasingly critical public health need. The challenge for healthcare professionals is identifying infected women, given that ~80% of cases are asymptomatic, compared to only 10-15% of asymptomatic cases in men.2 Despite the lack of immediate symptoms, if left untreated in women, gonorrhea can lead to painful pelvic inflammatory disease and infertility.

56%

 

Increase in gonorrhea cases in the US between 2015 and 20191

>50%

 

Of infections were resistant to at least one antibiotic in 20191

~80%

 

Of women and 10-15% of men infected with gonorrhea may be asymptomatic2

The Benefits of a Rapid Gonorrhea Test

 

One of the biggest challenges with treating gonorrhea is delivering timely results, preferably at the visit when the test is given. Several studies have shown that 20% or more of patients with positive STI tests fail to return for treatment3, which may in part be explained by the lack of immediate symptoms in women and the stigma associated with STIs as well as difficulties obtaining time off from work and finding transportation to the healthcare facility. These missed treatment opportunities most likely lead to additional disease transmission.

Delivering results during a patient visit has been problematic. Nucleic acid amplification tests (NAAT) are the current gold standard, but most NAATs for gonorrhea must be performed in a central lab, requiring patients to return to their health care provider for treatment should the results be positive. Diagnostic tests that could be performed at the point of care and provide results within minutes could help ensure more patients with gonorrhea receive treatment, potentially interrupting the transmission cycle.

“If an infected patient receives timely treatment at an initial visit, further transmission can be interrupted.”

-Barrow, et al.3

Rapid Gonorrhea Testing at the Point-of-Care

 

Designed to maximize health outcomes in the face of infectious diseases like gonorrhea, the Talis One™ instrument may enable fast, accurate, lab-quality molecular diagnostic testing in a variety of care settings.

We have already developed a Talis One COVID-19 Test System that was granted an Emergency Use Authorization (EUA) in the second half of 2021 and are developing a Talis One Gonorrhea Test System that is designed to bring rapid gonorrhea testing to sexually transmitted disease (STD) clinics, urgent care clinics, and primary care offices.

Talis One Point-of-care Instrument

 

The Talis One point-of-care instrument delivers rapid, reliable, and accurate, lab-quality diagnostic testing results across a variety of CLIA-waived care settings.

Talis One Consumables

 

The Talis One Nasal Mid-Turbinate Collection Kit stabilizes viral RNA and inactivates viruses.1 Each single-use cartridge contains a highly sensitive, solid-phase nucleic acid amplification test (NAAT). 

Dedicated Talis One Customer Support

 

Our Customer Service support team is happy to help answer your questions.

The Talis One system is poised to help you break the cycle of transmission of STIs. Tell us what capabilities you’d like to see in a point-of-care gonorrhea test.

Get In Touch

Join Our Newsletter

Subscribe to our newsletter for information about our products and company updates.

    TALIS BIOMEDICAL

    The GenBody COVID-19 Ag Test and the Talis One COVID-19 Test System are for use under Emergency Use Authorization (EUA) only. For In Vitro Diagnostic (IVD) use. For prescription use only. Talis is an authorized distributor of the GenBody COVID-19 Ag test.

    © Talis and Talis One are trademarks of Talis Biomedical Corporation. All Rights Reserved.

    *Additional testing solutions are currently in development and not available for sale.

    References

    1. National Overview – Sexually Transmitted Disease Surveillance, 2019. Centers for Disease Control and Prevention. Published April 2021. Accessed July 29, 2021.
    2. Fact sheet: Gonorrhea Gonococcal Infection (clap, drip). New York State Department of Health. Last reviewed 2006. Accessed July 29, 2021.
    3. Barrow RY, et al. Recommendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020. MMWR Recomm Rep. 2020 Jan 3;68(5):1-20. PMCID: PMC6950496